jeudi 19 mars 2020

Onco Actu du 19 mars 2020


4.1 DÉP., DIAG. & PRONO. - PROSTATE



NCCN Updates Professional Guidelines Recommending Biomarker Testing for Unfavorable Intermediate and High-Risk Patients with Prostate Cancer [Myriad]











4.11 DÉP., DIAG. & PRONO. - OVAIRE



New research shows which ovarian cancer patients won't benefit from immune-PARP combo [EurekAlert!]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



Researchers in Singapore find common therapeutic vulnerability for a genetically diverse and deadly leukaemia [Duke]











5.10 TRAITEMENTS - ESSAIS



In NIH trial, selumetinib shrinks tumors, provides clinical benefit for children with NF1 [NCI]










5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



Bristol Myers' Juno unit enlists Oxford BioMedica for CAR-T work [Fierce Pharma]











5.2.6 PHARMA - BIOTECH



Ex-Shire cancer leader raises cash for solid tumor research [Fierce Biotech]











Former Shire execs set up shop to take a shot at 'under the radar' cancer target [EndPoints]











6.15 LUTTE CONTRE LES CANCERS - COVID-19



As Covid-19 R&D goes into overdrive, nuts-and-bolts biopharma research is hitting the skids. How bad is it? [EndPoints]